Combigene AB Cash Flow Conversion Efficiency

Latest as of December 2024: -0.087x

Combigene AB cash flow conversion efficiency. Based on the latest financial reports, Combigene AB (COMBI) has a cash flow conversion efficiency ratio of -0.087x as of December 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-6.23 Million ≈ $-670.56K USD) by net assets (Skr71.58 Million ≈ $7.70 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Combigene AB (2012–2024)

Cash flow conversion efficiency of Combigene AB from 2012 to 2024. This chart illustrates how Combigene AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Combigene AB stock price for real-time trading data and today's change.

Combigene AB Cash Flow Conversion Ratio Explained

Combigene AB cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Combigene AB Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Combigene AB ranked by their cash flow conversion efficiency. Also see market value of Combigene AB for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
Bhakti Agung Propertindo JK:BAPI	-0.002x
VIA OPTRONICS AG SP.ADS/1 F:5UU1	N/A
Twin Vee Powercats Co NASDAQ:VEEE	-0.112x
ARK Resources Bhd KLSE:7007	-0.760x
Intertainment AG XETRA:ITN	0.016x
Gelteq Limited Ordinary Shares NASDAQ:GELS	-0.021x
Ladangbaja Murni PT Tbk JK:LABA	-0.054x
Union Pioneer Public Company Limited BK:UPF	-0.058x

Annual Cash Flow Conversion Efficiency for Combigene AB (2012–2024)

The table below shows the annual cash flow conversion efficiency of Combigene AB from 2012 to 2024. Review how much free cash does Combigene AB generate to assess how much free cash flow the company generates relative to operating cash flow.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	Skr71.58 Million ≈ $7.70 Million	Skr-29.95 Million ≈ $-3.22 Million	-0.418x	-59.46%
2023-12-31	Skr116.46 Million ≈ $12.53 Million	Skr-30.56 Million ≈ $-3.29 Million	-0.262x	-139.51%
2022-12-31	Skr152.12 Million ≈ $16.37 Million	Skr-16.67 Million ≈ $-1.79 Million	-0.110x	-178.41%
2021-12-31	Skr158.28 Million ≈ $17.03 Million	Skr22.11 Million ≈ $2.38 Million	0.140x	+126.03%
2020-12-31	Skr71.43 Million ≈ $7.69 Million	Skr-38.35 Million ≈ $-4.13 Million	-0.537x	+49.55%
2019-12-31	Skr20.30 Million ≈ $2.19 Million	Skr-21.60 Million ≈ $-2.33 Million	-1.064x	-9662.78%
2018-12-31	Skr20.46 Million ≈ $2.20 Million	Skr227.60K ≈ $24.49K	0.011x	+100.76%
2017-12-31	Skr6.51 Million ≈ $700.81K	Skr-9.53 Million ≈ $-1.03 Million	-1.463x	+32.24%
2016-12-31	Skr4.08 Million ≈ $439.02K	Skr-8.81 Million ≈ $-947.94K	-2.159x	-252.65%
2015-12-31	Skr10.27 Million ≈ $1.10 Million	Skr-6.29 Million ≈ $-676.42K	-0.612x	-458.89%
2014-12-31	Skr5.67 Million ≈ $609.68K	Skr-620.67K ≈ $-66.79K	-0.110x	+75.90%
2013-12-31	Skr598.60K ≈ $64.42K	Skr-272.15K ≈ $-29.29K	-0.455x	-328.90%
2012-12-31	Skr298.09K ≈ $32.08K	Skr59.21K ≈ $6.37K	0.199x	--

About Combigene AB

ST:COMBI Sweden Biotechnology

Market Cap

$5.24 Million

Skr48.71 Million SEK

Market Cap Rank

#28415 Global

#623 in Sweden

Share Price

Skr2.46

Change (1 day)

+0.00%

52-Week Range

Skr2.46 - Skr2.46

All Time High

Skr152.75